Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other 1NET 1Endocrine 1Dermatologic 1Breast 1

Conditions

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 70Letrozole 63Cyclophosphamide 61Paclitaxel 60Specimen Handling 54pertuzumab 52Docetaxel 50abemaciclib 46ribociclib 45Anastrozole 36Magnetic Resonance Spectroscopy 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Blood Specimen Collection 33exemestane 32Tamoxifen 32Biopsy 32sacituzumab govitecan 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Drug Therapy 28Surveys and Questionnaires 27Injections 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leflunomide × Breast × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡